The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer …
Background: The heterogeneity of Alzheimer disease requires the development of
multitarget drugs for treating the symptoms of the disease and its progression. Both …
multitarget drugs for treating the symptoms of the disease and its progression. Both …
Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro
I Bolea, A Gella, L Monjas, C Perez… - Current Alzheimer …, 2013 - ingentaconnect.com
Amyloid beta (Aβ) aggregation and deposition is a key pathological hallmark of AD. Growing
evidence suggests that neurotoxicity of this peptide is related to the formation of toxic …
evidence suggests that neurotoxicity of this peptide is related to the formation of toxic …
[HTML][HTML] Highlights of ASS234: A novel and promising therapeutic agent for Alzheimer's disease therapy
A Romero, J Marco-Contelles… - Neural Regeneration …, 2020 - journals.lww.com
There is no effective treatment to face Alzheimer's disease complexity. Multitarget molecules
are a good approach against the multiple physiopathological events associated with its …
are a good approach against the multiple physiopathological events associated with its …
Elevating acetyl-CoA levels reduces aspects of brain aging
Because old age is the greatest risk factor for dementia, a successful therapy will require an
understanding of the physiological changes that occur in the brain with aging. Here, two …
understanding of the physiological changes that occur in the brain with aging. Here, two …
[HTML][HTML] A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism
D Daugherty, J Goldberg, W Fischer… - Alzheimer's Research & …, 2017 - Springer
Background CAD-31 is an Alzheimer's disease (AD) drug candidate that was selected on
the basis of its ability to stimulate the replication of human embryonic stem cell-derived …
the basis of its ability to stimulate the replication of human embryonic stem cell-derived …
Dose-dependent improvements in learning and memory deficits in APPPS1-21 transgenic mice treated with the orally active Aβ toxicity inhibitor SEN1500
AC Lo, I Tesseur, DIC Scopes, E Nerou… - …, 2013 - Elsevier
In the Alzheimer's disease (AD) brain, accumulation of Aβ 1–42 peptides is suggested to
initiate a cascade of pathological events. To date, no treatments are available that can …
initiate a cascade of pathological events. To date, no treatments are available that can …
In-vitro and in-vivo evaluation of the modulatory effects of the multitarget compound ASS234 on the monoaminergic system
G Esteban, J Van Schoors, P Sun… - Journal of Pharmacy …, 2017 - academic.oup.com
Objectives To evaluate the in-vitro and in-vivo effects on monoaminergic neurotransmission
of ASS234, a promising multitarget-directed ligand (MTDL), for Alzheimer's disease (AD) …
of ASS234, a promising multitarget-directed ligand (MTDL), for Alzheimer's disease (AD) …
[HTML][HTML] Upregulation of antioxidant enzymes by ASS234, a multitarget directed propargylamine for Alzheimer's disease therapy
Alzheimer's disease (AD), a major neurodegenerative disorder, is a matter of health concern
because of the lack of effective drugs to treat it. Thus, our group has recently identified N-((5 …
because of the lack of effective drugs to treat it. Thus, our group has recently identified N-((5 …
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
NJ Izzo, CM Yuede, KM LaBarbera… - Alzheimer's & …, 2021 - Wiley Online Library
Introduction Amyloid beta (Aβ) oligomers are one of the most toxic structural forms of the Aβ
protein and are hypothesized to cause synaptotoxicity and memory failure as they build up …
protein and are hypothesized to cause synaptotoxicity and memory failure as they build up …
[CITATION][C] Preclinical Pharmacology of TAK‐147, a Novel Acetylcholinesterase Inhibitor, as a Potential Therapeutic Drug for Alzheimer's Disease
M Miyamoto, G Goto - CNS Drug Reviews, 1997 - Wiley Online Library
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive
deterioration of memory and cognition. Prominent histopathological features of AD include …
deterioration of memory and cognition. Prominent histopathological features of AD include …